Curzion Pharmaceuticals is a clinical-stage company, co-founded by Pappas Capital, focused on developing treatments for rare fibrotic diseases. The company’s lead asset is a potent and selective LPAR1 antagonist for the treatment of diffusive systemic sclerosis.